Skip to main content

Table 5 Average cost of managing HAE episodes with icatibant (Euros)

From: Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain

 

Most favourable scenario

Least favourable scenario

Variable

Strategy 1 (€)

Strategy 2 (€)

Savings (€)

Savings (%)

Strategy 1 (€)

Strategy 2 (€)

Savings (€)

Savings (%)

Direct costs

1,600.16

1,480.94

119.21

7.45

986.69

923.07

63.62

6.45

Medical

1,588.12

1,479.73

108.39

6.82

982.48

922.00

60.48

6.16

   Icatibant

1,468.59

1,468.59

0.00

0.00

901.85

901.85

0.00

0.00

   Visits*

114.33

11.07

103.26

90.32

79.54

20.07

59.47

74.77

   Admissions

4.91

0.07

4.84

98.60

0.82

0.05

0.77

93.78

   Tracheotomy

0.29

0.01

0.28

96.67

0.26

0.03

0.24

90.00

Non-medical

12.03

1.21

10.82

89.95

4.21

1.08

3.14

74.47

   Transportation

12.03

1.21

10.82

89.95

4.21

1.08

3.14

74.47

Indirect costs

64.05

13.47

50.58

78.97

25.21

9.34

15.87

62.95

   Caretaker

20.56

6.47

14.09

68.53

8.62

3.49

5,14

59.55

   Labor loss

18.98

6.18

12.80

67.45

9.19

3.63

5.56

60.46

   Death

24.50

0.82

23.69

96.67

7.39

2.22

5.17

70.00

Social costs

1,664.21

1,494.41

169.80

10.20

1,011.89

932.41

79.48

7.85

  1. Strategy 1= Health professional-administration only; Strategy 2= Self-administration also available.
  2. *Includes visits to hospital emergency rooms, primary care centres emergency rooms, and to HAE specialist offices.
  3. Sensitivity analysis.